Novo Nordisk scored a huge legal victory that largely restricts compounding pharmacies ... in those drugs, semaglutide, is no ...

Compounding pharmacies will no longer be allowed to create semaglutide injections, a generic and cheaper version of Ozempic and Wegovy. This comes after a judge rejected a bid by these pharmacies to ...

People who’ve been using more affordable copycat versions of Ozempic or Wegovy to lose ... it identified with compounded versions. The company has also nominated semaglutide to be included ...

When the FDA declared the shortage resolved for semaglutide, the main pharmaceutical ingredient in Wegovy and Ozempic, the agency gave 503B facilities until May 22 to stop making compounded versions.

The FDA's announcement that the shortage was resolved means compounding of semaglutide will no longer be permitted under current regulations. With cheaper versions of Wegovy no longer available ...

A federal judge April 24 rejected a bid by compounding pharmacies to continue selling less expensive copies of semaglutide, Novo Nordisk's blockbuster drug sold under the brands Wegovy and Ozempic.

Novo Nordisk appears to be letting compounded GLP-1 bygones ... of selling compounded versions of semaglutide, the drug better known as Novo’s blockbusters Wegovy and Ozempic.

Novo Nordisk scored a huge legal victory that largely restricts compounding ... semaglutide, is no longer in shortage in the U.S. Patients flocked to the cheaper copycats when Ozempic and Wegovy ...